

## Review Article

# Review of Hyperuricemia as New Marker for Metabolic Syndrome

**Laura Billiet, Sarah Doaty, James D. Katz, and Manuel T. Velasquez**

*Department of Medicine, The George Washington University, 2150 Pennsylvania Avenue, NW, Washington, DC 20037, USA*

Correspondence should be addressed to Laura Billiet; [lwbilliet@gwu.edu](mailto:lwbilliet@gwu.edu)

Received 5 August 2013; Accepted 12 December 2013; Published 16 February 2014

Academic Editors: C. V. Albanese, C.-J. Chen, and E. Tchetina

Copyright © 2014 Laura Billiet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hyperuricemia has long been established as the major etiologic factor in gout. In recent years, a large body of evidence has accumulated that suggests that hyperuricemia may play a role in the development and pathogenesis of a number of metabolic, hemodynamic, and systemic pathologic diseases, including metabolic syndrome, hypertension, stroke, and atherosclerosis. A number of epidemiologic studies have linked hyperuricemia with each of these disorders. In some studies, therapies that lower uric acid may prevent or improve certain components of the metabolic syndrome. There is an association between uric acid and the development of systemic lupus erythematosus; the connection between other rheumatic diseases such as rheumatoid arthritis and osteoarthritis is less clear. The mechanism for the role of uric acid in disorders other than gout is not well established but recent investigations point towards systemic inflammation induced by urate, as the major pathophysiological event common to systemic diseases, including atherosclerosis.

## 1. Introduction

More than 150 years ago, Garrod observed that uric acid is elevated in the blood of subjects with gout [1]. However, ultimate proof that uric acid is a causative factor in gout was not forthcoming for another 100 years when it was demonstrated that intra-articular injection of sodium urate produces acute arthritis [2]. Currently, it is well appreciated that chronic hyperuricemia enhances deposition of uric acid in tissues other than the joints, leading ultimately to tophi, nephropathy, and kidney stones.

## 2. Hyperuricemia Is Not Limited to Gout

In recent years there has been a renewed interest in hyperuricemia and its association with a number of clinical disorders other than gout, including hypertension, atherosclerosis, cardiovascular disease, and chronic kidney disease. Indeed, hyperuricemia is commonly part of the cluster of metabolic and hemodynamic abnormalities including abdominal obesity, glucose intolerance, insulin resistance, dyslipidemia, and hypertension all often subsumed under the term “metabolic

syndrome” [3, 4]. Not only collectively, but also individually, hypertension, obesity, dyslipidemia, hyperglycemia, and insulin resistance are positively correlated with serum levels of uric acid [5–9].

## 3. Hyperuricemia and Metabolic Syndrome and Its Components

The association between uric acid and metabolic syndrome is robust throughout human development. Epidemiological studies have demonstrated a close relationship between serum uric acid (SUA) levels and the presence of metabolic syndrome (and several of its components) among children and adolescents as well as adults [10]. Some studies have even noted the strong association between SUA and carotid atherosclerosis among obese children [10, 11]. One study analyzed the cross-sectional data of 1,370 US children and adolescents aged 12–17 years from the National Health and Nutrition Examination Survey (NHANES) 1999–2002 and found a graded positive association between SUA and the prevalence of metabolic syndrome or its components, independent of classical risk factors. They found that of the five

components of metabolic syndrome, SUA was significantly associated with abdominal obesity, hypertriglyceridemia, and hyperglycemia; there was only a borderline association observed between SUA and high blood pressure.

Another compelling evidence suggests that hyperuricemia predicts the development of hypertension, obesity, and type II diabetes mellitus [12, 13]. A prospective study from the Framingham Heart Study original ( $n = 4883$ ) and offspring ( $n = 4292$ ) cohorts showed that individuals with higher serum uric acid, including younger adults, had higher future risk of type 2 diabetes.

Several studies conducted since the early 1990s have shown that increased serum uric acid precedes the development of hypertension. Feig, in studies of hypertensive adolescents, reported that an elevated uric acid over 5.5 mg/dL was observed in 90% of adolescents with newly diagnosed primary disease [14]. Specifically, there exists a strong linear correlation between serum uric acid and systolic blood pressure. The same group conducted a double-blind, placebo-controlled crossover study including 30 hypertensive adolescents who were randomized to allopurinol or placebo for 4 weeks. While 86% of the intervention group became normotensive following a decrease of uric acid below 5 mg/dL, this rate was only 3% in the control arm [15]. Another intervention study conducted in asymptomatic hyperuricemic patients documented benefits with allopurinol treatment in terms of blood pressure and C-reactive protein (CRP). In a landmark animal study by Mazzali et al. pharmacologically induced mild-to-moderate hyperuricemia via oxonic acid administration in rats resulted in the development of hypertension. Remarkably when uric acid elevation was prevented by treating with allopurinol or with a uricosuric agent, the development of hypertension could be abrogated [16]. This study supports the hypothesis that there exists a direct causative role for uric acid in the development of hypertension. Collectively, these data strongly suggest that uric acid may have a pathogenic role in the development of metabolic syndrome and associated cardiovascular disease, rather than simply functioning as a surrogate marker for such disorders.

#### 4. Hyperuricemia in Rheumatic Diseases Other Than Gout

An association between hyperuricemia and rheumatic diseases, besides gouty arthritis, has been observed in epidemiologic studies. For example, in a study of 7374 adult women (age >20 yrs) in the Third National Health and Nutrition Examination Survey (NHANES), it was shown that women self-reporting RA had significantly higher SUA levels compared to women not self-reporting RA. In this study, predictors of SUA levels, besides self-reporting RA, were race/ethnicity, being married, smoking, use of alcohol, high body mass index, high C-reactive protein, elevated diastolic or systolic blood pressure, and increased glomerular filtration rate [17]. Furthermore, among patients with RA, one study has shown that SUA levels are correlated with the risk of renal dysfunction. SUA, independent of GFR, age, systolic blood

pressure, total cholesterol, triglycerides, and RA duration, was determined to be a risk factor for kidney disease [18].

Similarly, Yang et al. demonstrated that SUA levels can be used to predict the development of renal disease in patients with SLE. The authors found that SUA is independently associated with the development of lupus nephritis in SLE patients [19].

There are also reports showing an association between uric acid and osteoarthritis (OA). One study in OA patients with hip replacement found that elevated SUA concentrations were associated with the presence of multijoint hand OA [20]. Another study has shown the occurrence of gout attacks in joint sites that demonstrated radiographical OA such as big toe, midfoot, knee, and distal finger joints. It is possible that OA may facilitate the localized deposition of urate crystals [21].

More recently, Denoble et al. assessed synovial fluid UA concentration in patients with knee OA but with no clinical signs for, or self-report of, gout and found that synovial fluid UA concentrations correlated positively with radiographic and scintigraphic measures of OA severity and synovial fluid interleukins (IL-18 and IL-1 $\beta$ ) [22].

These findings suggest that synovial fluid UA is a risk marker for OA severity. Furthermore, they show a correlation between synovial fluid UA and IL-18 and IL-1 $\beta$ , two cytokines known to be produced by uric acid-activated inflammasomes. The association of synovial fluid IL-18 with OA progression also suggests the possibility that UA is a risk factor promoting the pathological process of OA (possibly through activation of the inflammasome).

#### 5. Biochemistry and Biological Actions of Uric Acid

Uric acid is the end product of purine metabolism in humans and is generated by the action of the enzyme, xanthine oxidase (XO), which catalyzes the last two steps of uric acid conversion: hypoxanthine to xanthine and from xanthine to uric acid.

For many years, uric acid was regarded as a metabolically inert substance. However, there is ample evidence that uric acid has multiple actions impacting cellular metabolism. For example, uric acid can act as an endogenous antioxidant and a powerful scavenger of single oxygen peroxy (ROS) and hydroxyl radicals (OH) [23]. Uric acid reacts with peroxynitrite and stabilizes endothelial nitric oxide synthase (eNOS) activity [24]. Its chemical limitations include the fact that uric acid cannot scavenge superoxide and that the presence of ascorbic acid in the plasma is required for its antioxidant effect. Finally, uric acid paradoxically behaves as a prooxidant and proinflammatory factor. A few points should be emphasized to better understand this apparent contradiction. First, uric acid functions differently inside cells versus the extracellular milieu, where it is present in soluble form [25]. Although it is a potent antioxidant in extracellular fluid, uric acid exerts prooxidative effects once inside the cell [26]. This effect is mediated by a NADPH oxidase-dependent pathway. It has been demonstrated that

plasma uric acid is a circulating marker of oxidant damage in a variety of pathological conditions, including, among others, ischemic liver injury, ischemic-reperfusion injury, hyperlipidemia, chronic heart failure, atherosclerosis, and diabetes [27–31]. Thus, inhibition of XOR by allopurinol or other XOR inhibitors would be expected to reduce not only uric acid production but also NADH, which results in a favorable shift of NAD/NADH ratio.

## 6. Hyperuricemia and Atherosclerosis

Serum uric acid levels have an association with surrogate markers of atherosclerosis in a number of studies. Surrogate markers of atherosclerosis shown to have an association with hyperuricemia include carotid intima-media thickness (C-IMT) [11, 32–36], ankle brachial index [34], coronary artery calcification [37], and brachial-ankle pulse wave velocity (baPWV) [38]. In addition, many studies suggest an independent effect of elevated serum uric acid on atherosclerosis as measured by these surrogate markers after adjusting for the influence of metabolic syndrome and other factors [11, 33, 35, 39]. In particular, there is evidence that uric acid has direct effects on key processes involved in endothelial function and vascular remodeling [40].

Xanthine oxidoreductase has two forms. In physiologic conditions, it exists primarily as xanthine dehydrogenase, which has greater affinity for oxidized nicotinamide adenine reductase (NAD<sup>+</sup>) compared to oxygen. Under ischemic conditions, xanthine dehydrogenase is converted to xanthine oxidase. Xanthine oxidase uses oxygen as an electron acceptor instead of NAD<sup>+</sup> resulting in the formation of superoxide anion and hydrogen peroxide alongside uric acid. It is unclear whether the resulting inflammation and arterial wall damage associated with hyperuricemia are related to the free radicals formed or to the uric acid itself [41].

As noted above, uric acid has both prooxidant and antioxidant activity. When acting an antioxidant, it chelates metals and scavenges oxygen radicals [42]. As a prooxidant, uric acid oxidizes lipids [43], reduces nitric oxide availability in endothelial cells [44], and increases reactive oxygen species [45]. Furthermore, as a prooxidant, high levels of serum uric acid cause increased lipid oxidation [43]. The resultant inflammation would be expected to disrupt reverse cholesterol transport, a function that is important to reduce cardiovascular risk [46].

Oxidants also cause endothelial dysfunction by reacting with and removing NO, thereby preventing vasodilation of the endothelium. Decreased NO and increased reactive oxygen species may promote a proinflammatory state that causes endothelial dysfunction and contributes to atherosclerosis and cardiovascular disease [47]. Finally, uric acid inhibits endothelial cell proliferation and stimulates C-reactive protein production in endothelial cells [48].

At the level of vascular smooth muscle cells, uric acid stimulates the production of monocyte chemoattractant protein-1 (MCP-1), a key chemokine implicated in atherosclerosis and chronic kidney disease. Increased production of MCP-1 by uric acid appears to be mediated via

activation of mitogen-activated protein (MAP) kinase and cyclooxygenase-2, leading to increased cell proliferation and production of CRP and other inflammatory mediators [48]. Taken together, it is not surprising that several studies show that elevated serum uric acid levels are predictive of atherosclerosis or cardiovascular disease. For example, hypertensive hyperuricemic patients have higher levels of BMI, C-IMT, fasting plasma glucose, UA, hs-CRP, and proteinuria as compared with hypertensive normouricemic subjects. Hyperuricemia, *per se*, was found to be an independent predictor for atherosclerosis in patients with hypertension [33]. In another clinical study, serum uric acid was found to be associated with subclinical atherosclerosis in men with type II diabetes mellitus [34, 49]. Serum uric acid levels were also higher in patients with rheumatoid arthritis (RA) and cardiovascular disease than in those without cardiovascular disease despite the fact that RA is not usually associated with high serum uric acid levels [50]. Such findings do not appear to be limited by gender. In women with systemic lupus erythematosus, serum uric acid was found to be associated with arterial stiffness and of potential use as an indicator of subclinical atherosclerosis, although it was not independent of age and homocysteine levels [51], nor is it likely the situation that an absolute level of uric acid elevation is necessary for injurious outcome. This was seen in a population of psoriatic arthritis patients with subclinical atherosclerosis [52]. Of note, most of the patients in this study had serum uric acid levels that were in the normal reference range even though there remained a link between subclinical atherosclerosis and serum uric acid concentration [52]. This may mean that the reference ranges for patients with chronic inflammatory diseases may need to be adjusted. At the very least, elevated levels of serum uric acid, even if within the reference range, may need to be considered more carefully in populations at higher risk for cardiovascular disease.

In summary, while it may be true that, under normal physiologic conditions, uric acid functions as an antioxidant and protects against atherosclerosis, it appears that, under ischemic conditions, it becomes a prooxidant and increases the risk of atherosclerosis [41].

Hence, it is as yet unclear what the role of lowering uric acid may be in reducing cardiovascular disease risk. Further study is needed to show if lowering serum uric acid will also lower the incidence of atherosclerosis and cardiovascular disease.

## 7. Urate as a Mediator of Inflammation

We now turn our attention to the involvement of uric acid in systemic inflammation: a central pathophysiological feature common to many forms of chronic noninfectious disorders such as obesity, hypertension, chronic heart failure, and cardiovascular disease, as well as generalized atherosclerosis. Indeed, there are epidemiological studies showing a relationship between serum uric acid and markers of systemic inflammation. In several population-based studies [53] in

healthy men and women, serum uric acid is associated positively with CRP [54]. Similarly, serum uric acid is positively associated not only with CRP, but also with IL-6 and TNF- $\alpha$ , as reported in a study of 957 elderly individuals in Italy [55]. Moreover, serum uric acid predicted CRP increase during follow-up assessment [30]. In another population-based study conducted in Switzerland that included 6085 Caucasians aged 35 to 75 years, serum uric acid was found to be positively associated with CRP, TNF- $\alpha$ , and IL-6 (in both men and women) [56]. In patients with chronic heart failure, SUA is associated positively with TNF- $\alpha$  and IL-6. And in patients with metabolic syndrome, several components of the syndrome, including serum uric acid levels, are strongly correlated with serum levels of CRP, IL-6, and fibrinogen, again, consistent with high inflammatory activity [57]. Finally, there is experimental evidence that suggests that uric acid can directly stimulate the release of TNF- $\alpha$ . Specifically, infusion of soluble uric acid into mice produces a marked increase in circulating TNF- $\alpha$  levels [58]. Studies by di Giovine et al. have demonstrated that urate crystals stimulate production of TNF- $\alpha$  from human blood monocytes and synovial cells [59]. Along similar lines, cell culture experiments by Bordoni et al. have highlighted the role of uric acid in inflammation by demonstrating its role in signal transduction within the apoptotic pathway and also confirming that uric acid stimulates mononuclear cells to produce TNF- $\alpha$  [60].

Recently, Kono and coworkers, in a series of *in vivo* studies, demonstrated that uric acid plays a key role in the inflammatory response to necrotic cells in mice. These investigators found that dead cells not only release intracellular stores of uric acid but also produce it in large amounts post-mortem (as nucleic acids were degraded) [61]. Using a newly developed transgenic (Tg) mouse that has reduced levels of uric acid, they further showed that uric acid depletion substantially reduces the cell death-induced inflammatory response. Similar results have been obtained with pharmacological treatments that reduced uric acid levels by either blocking its synthesis or hydrolyzing it in the extracellular fluids. Additionally, uric acid depletion selectively inhibits the inflammatory response to dying cells but not to microbial molecules or sterile irritant particles. Taken together, these data indicate that uric acid acts as an endogenous proinflammatory molecule released from dying cells as a result of tissue damage.

Recently, a critical role of intracellular inflammasomes (such as NALP3) has been identified. Innate immune complexes known to be responsible for triggering inflammation in response to danger-associated molecular patterns (DAMPs) have been implicated in MSU crystal associated inflammation [62, 63]. The inflammatory effect of MSU crystals appears to be mediated to a large extent by the NLRP3 inflammasome that drives IL-1 $\beta$  and IL-18 production. IL-1 $\beta$  is likely the main agent to trigger systemic inflammation, promoting extensive neutrophil infiltration and tissue restructuring [64]. Further evidence for a role of UA in inflammasome activation is the finding that inflammasome activation by pure synthetic hemozoin is reduced by allopurinol [65].

## 8. Urate and Innate and Adaptive Immunity

Uric acid is a danger signal that alerts the immune system to cell injury and triggers both innate and adaptive immune responses. It has been shown that dying cells injected into animals along with an antigen create a strong adjuvant effect and significantly increase the immune response to the initial antigen. Microcrystalline UA released from injured cells may be the danger signal triggering this adjuvant effect through the stimulation of CD8+ T cells [66].

Studies by Liu-Bryan et al. also implicate innate immune cellular recognition of naked MSU crystals by specific Toll-like receptors (TLRs) as a major factor in determining the inflammatory potential of MSU crystal deposits [67]. Recently it was shown that UA crystals in the presence of NF- $\kappa$ B signaling were capable of stimulating dendritic cells to promote the release of cytokines associated with Th17 polarization indicating, a novel role for UA in driving proinflammatory Th17, suggesting that sterile inflammation modulates adaptive immunity, in addition to influencing early innate responses [68].

In summary, evidence has emerged that points towards a new interpretation of the pathophysiological role of uric acid. No longer can we view it simply as a phenomenon restricted to gout, but rather as an active agent involved in systemic inflammatory and innate immune responses. It is becoming clear that uric acid is not only a marker of the metabolic syndrome and associated cardiovascular risk factors, but also an agent provocateur of systemic inflammation and the innate immune response that contributes to the development and pathogenesis of cardiovascular disease. Indeed, it may be a key measure of blood vessel inflammation. This has implications not only for the metabolic syndrome (and accelerated atherosclerosis) but likely also for autoimmune vascular diseases such as vasculitis. Therefore, it is not surprising that patients with SLE and metabolic syndrome have significantly raised serum uric acid [69].

In short, an inflammatory microangiopathy may be seen in patients with connective tissue disease and uric acid may be an active participant in the process. It may be that physiologic signal transduction mediated by reactive oxygen species (ROS) along with the possibility of rapid XD to XO conversion plays a role as a trigger for the microvascular inflammatory response to clinical states of vascular injury [70].

## Conflict of Interests

The authors have no financial interest in the subject matter or materials discussed in this paper.

## References

- [1] A. Garrod, "Observations on certain pathological conditions of the blood and urine, in gout, rheumatism and Bright's disease," *Medico-Chirurgical Transactions*, vol. 31, pp. 83–97, 1848.
- [2] J. S. Faires and D. Mccarty Jr., "Acute arthritis in man and dog after intrasynovial injection of sodium urate crystals," *The Lancet*, vol. 280, no. 7258, pp. 682–685, 1962.

- [3] H. K. Choi and E. S. Ford, "Prevalence of the metabolic syndrome in individuals with hyperuricemia," *The American Journal of Medicine*, vol. 120, no. 5, pp. 442–447, 2007.
- [4] G. M. Reaven, "Role of insulin resistance in human disease (syndrome X): an expanded definition," *Annual Review of Medicine*, vol. 44, pp. 121–131, 1993.
- [5] S.-D. Lin, D.-H. Tsai, and S.-R. Hsu, "Association between serum uric acid level and components of the metabolic syndrome," *Journal of the Chinese Medical Association*, vol. 69, no. 11, pp. 512–516, 2006.
- [6] T. W. Yoo, K. C. Sung, H. S. Shin et al., "Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome," *Circulation Journal*, vol. 69, no. 8, pp. 928–933, 2005.
- [7] A. Onat, H. Uyarel, G. Hergenc et al., "Serum uric acid is a determinant of metabolic syndrome in a population-based study," *American Journal of Hypertension*, vol. 19, no. 10, pp. 1055–1062, 2006.
- [8] T. Kawada, T. Otsuka, M. Katsumata, and H. Suzuki, "Serum uric acid is significantly related to the components of the metabolic syndrome in Japanese workingmen," *Journal of the Cardiometabolic Syndrome*, vol. 2, no. 3, pp. 158–162, 2007.
- [9] V. Bhole, J. W. Choi, S. W. Kim, M. de Vera, and H. Choi, "Serum uric acid levels and the risk of type 2 diabetes: a prospective study," *The American Journal of Medicine*, vol. 123, no. 10, pp. 957–961, 2010.
- [10] E. S. Ford, C. Li, S. Cook, and H. K. Choi, "Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents," *Circulation*, vol. 115, no. 19, pp. 2526–2532, 2007.
- [11] L. Pacifico, V. Cantisani, C. Anania et al., "Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children," *European Journal of Endocrinology*, vol. 160, no. 1, pp. 45–52, 2009.
- [12] W. Rathmann, E. Funkhouser, A. R. Dyer, and J. M. Roseman, "Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults," *Annals of Epidemiology*, vol. 8, no. 4, pp. 250–261, 1998.
- [13] C. Oyama, T. Takahashi, M. Oyamada et al., "Serum uric acid as an obesity-related indicator in early adolescence," *Tohoku Journal of Experimental Medicine*, vol. 209, no. 3, pp. 257–262, 2006.
- [14] D. I. Feig, "Hypertension in adolescents," *Seminars in Nephrology*, vol. 25, no. 1, pp. 32–38, 2005.
- [15] D. I. Feig, B. Soletsky, and R. J. Johnson, "Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial," *The Journal of the American Medical Association*, vol. 300, no. 8, pp. 924–932, 2008.
- [16] M. Mazzali, J. Hughes, Y.-G. Kim et al., "Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism," *Hypertension*, vol. 38, no. 5, pp. 1101–1106, 2001.
- [17] J. H. Magnus, M. K. Doyle, and S. K. Srivastav, "Serum uric acid and self-reported rheumatoid arthritis in a multiethnic adult female population," *Current Medical Research and Opinion*, vol. 26, no. 9, pp. 2157–2163, 2010.
- [18] D. Daoussis, V. Panoulas, T. Toms et al., "Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 11, no. 4, article R116, 2009.
- [19] Z. Yang, Y. Liang, W. Xi, Y. Zhu, C. Li, and R. Zhong, "Association of serum uric acid with lupus nephritis in systemic lupus erythematosus," *Rheumatology International*, vol. 31, no. 6, pp. 743–748, 2011.
- [20] Y. Sun, H. Brenner, S. Sauerland, K. P. Günther, W. Puhl, and T. Stürmer, "Serum uric acid and patterns of radiographic osteoarthritis—the Ulm Osteoarthritis Study," *Scandinavian Journal of Rheumatology*, vol. 29, no. 6, pp. 380–386, 2000.
- [21] E. Roddy, W. Zhang, and M. Doherty, "Are joints affected by gout also affected by osteoarthritis?" *Annals of the Rheumatic Diseases*, vol. 66, no. 10, pp. 1374–1377, 2007.
- [22] A. E. Denoble, K. M. Huffman, T. V. Stabler et al., "Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 5, pp. 2088–2093, 2011.
- [23] Y. Y. Sautin, T. Nakagawa, S. Zharikov, and R. J. Johnson, "Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress," *American Journal of Physiology*, vol. 293, no. 2, pp. C584–C596, 2007.
- [24] N. Kuzkaya, N. Weissmann, D. G. Harrison, and S. Dikalov, "Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase," *Biochemical Pharmacology*, vol. 70, no. 3, pp. 343–354, 2005.
- [25] R. J. Johnson, C. Rivard, T. Nakagawa, Y. Y. Sautin, and L. G. Sanchez-Lozada, "Uric acid: more to learn, more experiments to do," *American Journal of Hypertension*, vol. 22, no. 9, pp. 952–953, 2009.
- [26] C. Schorn, C. Janko, L. Munoz et al., "Sodium and potassium urate crystals differ in their inflammatory potential," *Autoimmunity*, vol. 42, no. 4, pp. 314–316, 2009.
- [27] F. Leyva, S. D. Anker, I. F. Godstrand et al., "Uric acid in chronic heart failure: a marker of chronic inflammation," *European Heart Journal*, vol. 19, no. 12, pp. 1814–1822, 1998.
- [28] P. Olexa, M. Olexová, J. Gonsorčík, I. Tkáč, J. Kisel'ová, and M. Olejníková, "Uric acid—a marker for systemic inflammatory response in patients with congestive heart failure?" *Wiener Klinische Wochenschrift*, vol. 114, no. 5–6, pp. 211–215, 2002.
- [29] C. Ruggiero, A. Cherubini, A. Ble et al., "Uric acid and inflammatory markers," *European Heart Journal*, vol. 27, no. 10, pp. 1174–1181, 2006.
- [30] C. Ruggiero, A. Cherubini, E. Miller III et al., "Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years," *American Journal of Cardiology*, vol. 100, no. 1, pp. 115–121, 2007.
- [31] T. Lyngdoh, P. Marques-Vidal, F. Paccaud et al., "Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based colaus study," *PLoS ONE*, vol. 6, no. 5, Article ID e19901, 2011.
- [32] Z. Zhang, L. Bian, and Y. Choi, "Serum uric acid: a marker of metabolic syndrome and subclinical atherosclerosis in Korean men," *Angiology*, vol. 63, no. 6, pp. 420–428, 2012.
- [33] R. Mutluay, S. M. Deger, E. Bahadir, A. O. Durmaz, R. Çitil, and S. Sindel, "Uric acid is an important predictor for hypertensive early atherosclerosis," *Advances in Therapy*, vol. 29, no. 3, pp. 276–286, 2012.
- [34] M. Fukui, M. Tanaka, E. Shiraishi et al., "Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus," *Metabolism*, vol. 57, no. 5, pp. 625–629, 2008.

- [35] W. Doehner, N. Schoene, M. Rauchhaus et al., "Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies," *Circulation*, vol. 105, no. 22, pp. 2619–2624, 2002.
- [36] D. Erdogan, H. Gullu, M. Caliskan et al., "Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults," *International Journal of Clinical Practice*, vol. 59, no. 11, pp. 1276–1282, 2005.
- [37] E. Krishnan, B. J. Pandya, L. Chung, and O. Dabbous, "Hyperuricemia and the risk for subclinical coronary atherosclerosis—data from a prospective observational cohort study," *Arthritis Research & Therapy*, vol. 13, no. 2, article R66, 2011.
- [38] N. Ishizaka, Y. Ishizaka, E.-I. Toda, H. Hashimoto, R. Nagai, and M. Yamakado, "Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals," *Atherosclerosis*, vol. 192, no. 1, pp. 131–137, 2007.
- [39] S. Takayama, R. Kawamoto, T. Kusunoki, M. Abe, and M. Onji, "Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome," *Cardiovascular Diabetology*, vol. 11, article 2, 2012.
- [40] D.-H. Kang, S.-K. Park, I.-K. Lee, and R. J. Johnson, "Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells," *Journal of the American Society of Nephrology*, vol. 16, no. 12, pp. 3553–3562, 2005.
- [41] G. K. Glantzounis, E. C. Tsimoyiannis, A. M. Kappas, and D. A. Galaris, "Uric acid and oxidative stress," *Current Pharmaceutical Design*, vol. 11, no. 32, pp. 4145–4151, 2005.
- [42] A. So and B. Thorens, "Uric acid transport and disease," *The Journal of Clinical Investigation*, vol. 120, no. 6, pp. 1791–1799, 2010.
- [43] M. Bagnati, C. Perugini, C. Cau, R. Bordone, E. Albano, and G. Bellomo, "When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid," *Biochemical Journal*, vol. 340, no. 1, pp. 143–152, 1999.
- [44] U. M. Khosla, S. Zharikov, J. L. Finch et al., "Hyperuricemia induces endothelial dysfunction," *Kidney International*, vol. 67, no. 5, pp. 1739–1742, 2005.
- [45] C. R. White, T. A. Brock, L. Y. Chang et al., "Superoxide and peroxynitrite in atherosclerosis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 3, pp. 1044–1048, 1994.
- [46] F. C. McGillicuddy, M. L. de La Moya, C. C. Hinkle et al., "Inflammation impairs reverse cholesterol transport in vivo," *Circulation*, vol. 119, no. 8, pp. 1135–1145, 2009.
- [47] R. J. Johnson, D.-H. Kang, D. Feig et al., "Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?" *Hypertension*, vol. 41, no. 6, pp. 1183–1190, 2003.
- [48] J. Kanellis, S. Watanabe, J. H. Li et al., "Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2," *Hypertension*, vol. 41, no. 6, pp. 1287–1293, 2003.
- [49] Q. Li, Z. Yang, B. Lu et al., "Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes," *Cardiovascular Diabetology*, vol. 10, article 72, 2011.
- [50] V. F. Panoulas, H. J. Milionis, K. M. J. Douglas et al., "Association of serum uric acid with cardiovascular disease in rheumatoid arthritis," *Rheumatology*, vol. 46, no. 9, pp. 1466–1470, 2007.
- [51] J. M. Sabio, J. A. Vargas-Hitos, J. D. Mediavilla et al., "Correlation of asymptomatic hyperuricaemia and serum uric acid levels with arterial stiffness in women with systemic lupus erythematosus without clinically evident atherosclerotic cardiovascular disease," *Lupus*, vol. 19, no. 5, pp. 591–598, 2010.
- [52] M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., "Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease," *Seminars in Arthritis and Rheumatism*, vol. 39, no. 3, pp. 157–162, 2009.
- [53] C. K. Kramer, D. von Mühlen, S. K. Jassal, and E. Barrett-Connor, "Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study," *Diabetes Care*, vol. 32, no. 7, pp. 1272–1273, 2009.
- [54] Y. J. Lee, J. H. Lee, Y. H. Shin, J.-K. Kim, H.-R. Lee, and D.-C. Lee, "Gender difference and determinants of C-reactive protein level in Korean adults," *Clinical Chemistry and Laboratory Medicine*, vol. 47, no. 7, pp. 863–869, 2009.
- [55] E. Bonora, G. Targher, M. B. Zenere et al., "Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study," *International Journal of Obesity and Related Metabolic Disorders*, vol. 20, no. 11, pp. 975–980, 1996.
- [56] T. Lyngdoh, P. Marques-Vidal, F. Paccaud et al., "Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based colaus study," *PLoS ONE*, vol. 6, no. 5, Article ID e19901, 2011.
- [57] B. Kirilmaz, F. Asgun, E. Alioglu et al., "High inflammatory activity related to the number of metabolic syndrome components," *The Journal of Clinical Hypertension*, vol. 12, no. 2, pp. 136–144, 2010.
- [58] M. G. Netea, B. J. Kullberg, W. L. Blok, R. T. Netea, and J. W. M. van der Meer, "The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice," *Blood*, vol. 89, no. 2, pp. 577–582, 1997.
- [59] F. S. di Giovine, S. E. Malawista, E. Thornton, and G. W. Duff, "Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution," *The Journal of Clinical Investigation*, vol. 87, no. 4, pp. 1375–1381, 1991.
- [60] V. Bordoni, M. de Cal, M. Rattu et al., "Protective effect of urate oxidase on uric acid induced-monocyte apoptosis," *Current Drug Discovery Technologies*, vol. 2, no. 1, pp. 29–36, 2005.
- [61] H. Kono, C.-J. Chen, F. Ontiveros, and K. L. Rock, "Uric acid promotes an acute inflammatory response to sterile cell death in mice," *The Journal of Clinical Investigation*, vol. 120, no. 6, pp. 1939–1949, 2010.
- [62] F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, "Gout-associated uric acid crystals activate the NALP3 inflammasome," *Nature*, vol. 440, no. 7081, pp. 237–241, 2006.
- [63] H. M. Hoffman, P. Scott, J. L. Mueller et al., "Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice," *Arthritis & Rheumatism*, vol. 62, no. 7, pp. 2170–2179, 2010.
- [64] F. Ghaemi-Oskouie and Y. Shi, "The role of uric acid as an endogenous danger signal in immunity and inflammation," *Current Rheumatology Reports*, vol. 13, no. 2, pp. 160–166, 2011.

- [65] J. W. Griffith, T. Sun, M. T. McIntosh, and R. Bucala, "Pure hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid," *The Journal of Immunology*, vol. 183, no. 8, pp. 5208–5220, 2009.
- [66] Y. Shi, J. E. Evans, and K. L. Rock, "Molecular identification of a danger signal that alerts the immune system to dying cells," *Nature*, vol. 425, no. 6957, pp. 516–521, 2003.
- [67] R. Liu-Bryan, P. Scott, A. Sydlaske, D. M. Rose, and R. Terkeltaub, "Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation," *Arthritis & Rheumatism*, vol. 52, no. 9, pp. 2936–2946, 2005.
- [68] C. Conforti-Andreoni, R. Spreafico, H. L. Qian et al., "Uric acid-driven Th17 differentiation requires inflammasome-derived IL-1 and IL-18," *The Journal of Immunology*, vol. 187, no. 11, pp. 5842–5850, 2011.
- [69] M. Lozovoy, A. Simão, M. S. Hohmann et al., "Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome," *Lupus*, vol. 20, no. 13, pp. 1356–1364, 2011.
- [70] A. Meneshian and G. B. Bulkley, "The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction," *Microcirculation*, vol. 9, no. 3, pp. 161–175, 2002.



**Hindawi**  
Submit your manuscripts at  
<http://www.hindawi.com>

